Search Results

You are looking at 101 - 110 of 756 items for :

  • "radiation therapy" x
Clear All
Full access

David H. Moore

DH . Combined chemotherapy and radiation therapy for cervical cancer . J Natl Compr Canc Netw 2004 ; 2 : 631 – 635 . 12. National Cancer Institute . Concurrent chemoradiation for cervical cancer . Clinical Announcement , Washington

Full access

Puneeth Iyengar and Robert D. Timmerman

The concept of stereotactic ablative radiotherapy (SABR), known in older reports as stereotactic body radiation therapy (SBRT), for the treatment of lung cancer traces its roots back to the use of stereotactic radiosurgery in the treatment of

Full access

Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Rachel Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, Roy Decker, Jeffrey M. Farma, Kris Fisher, Brian Gastman, Karthik Ghosh, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Manisha Loss, Daniel D. Lydiatt, Jane Messina, Kishwer S. Nehal, Paul Nghiem, Igor Puzanov, Chrysalyne D. Schmults, Ashok R. Shaha, Valencia Thomas, Yaohui G. Xu, John A. Zic, Karin G. Hoffmann and Anita M. Engh

primary and postoperative treatment of the primary site and draining lymph node basin are detailed in the algorithm under “Principles of Radiation Therapy” (see pages 750 and 751). Recommended doses depend on the extent of disease, with higher doses

Full access

Taofeek K. Owonikoko and Suresh Ramalingam

; 103 : 2349 – 2354 . 47. Schild SE Bonner JA Hillman S . Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53) . J Clin Oncol

Full access

Jeffrey F. Moley

confirm the indolent nature of the disease and suggest the benefit of therapeutic interventions that keep tumor burden at a minimum (reoperative surgery when technically possible, cytostatic agents, selective use of external-beam radiation therapy [EBRT

Full access

Shailender Bhatia and John A. Thompson

as surgery or radiation therapy, may provide palliation of symptoms caused by local tumor growth, the cornerstone of treatment for metastatic melanoma is systemic therapy to address the clinical and subclinical sites of metastases. Chemotherapeutic

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel and Chun Chao

or more of these pathogenic states may also increase risk of FN during chemotherapy. Specifically, we hypothesize that surgery, radiation therapy (RT), use of corticosteroids and antibiotics, and certain dermatologic/mucosal conditions might increase

Full access

Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell and Stephen Leong

STRENGTH pathway, a retrospective QI analysis assessed an equal number of patients in the pre-STRENGTH and STRENGTH group for chemotherapy and radiation therapy dose intensities, as well as treatment outcomes. Results: During the pre-STRENGTH period

Full access

John Khoury, David Macari, Daniel Ezekwudo, Ayoda Werede and Ishmael A. Jaiyesimi

therapy was administered to 30.5% of the patients, of which 44.2% received chemoradiation, 48% chemotherapy only, and 7.2% radiation therapy only. After a median follow up of 39 months, the median overall survival (OS) was not reached in the group of

Full access

capecitabine and radiation therapy to patients with non-metastatic pancreatic cancer. Patients receive oral capecitabine twice daily and undergo high-dose hypofractionated radiotherapy once daily on days 1–5 and 8–12. Patients also receive oral vorinostat